Balancing the Risks and Benefits of Benzodiazepines
If you need an accessible version of this item, please email your request to digschol@iu.edu so that they may create one and provide it to you.
Date
2021-01
Language
English
Embargo Lift Date
Department
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
AMA
Abstract
In September 2020, the US Food and Drug Administration (FDA) announced an anticipated update to the boxed warning on all benzodiazepines to explicitly “address the serious risks of abuse, addiction, physical dependence, and withdrawal reactions” among this class of medications.1 The current boxed warning for benzodiazepines (eg, alprazolam, lorazepam, clonazepam, diazepam) highlights only the risks of coadministration of opioids and benzodiazepines. Benzodiazepines are prescribed for multiple indications, most notably generalized anxiety disorder, panic, social phobia, insomnia, and seizure prophylaxis and rescue.
Description
Keywords
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Hirschtritt, M. E., Olfson, M., & Kroenke, K. (2021). Balancing the Risks and Benefits of Benzodiazepines. JAMA, 325(4), 347–348. https://doi.org/10.1001/jama.2020.22106
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
JAMA
Source
Publisher
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
Version
Final published version